Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Averell

Neurology Akron, OH Doctor of Osteopathy

NPI 1891742763 CMS profile 616423

701 White Pond Dr Ste 300, Akron, OH 44320

Open in the dashboard

General payments

$25,589

1,071 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Averell of Akron, OH is reported in the CMS Open Payments database as having received $25,589 across 1,071 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,139 379
2024 General $7,367 358
2023 General $4,024 225
2022 General $1,486 90
2021 General $423 18
2019 General $150 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Averell
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Brian Averell were reported at $12,139. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Brian Averell Neurology median Middle half National median
2019 $150 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $423 $438 $104–$2,547 $132
2022 $1,486 $442 $103–$2,388 $149
2023 $4,024 $464 $119–$2,312 $160
2024 $7,367 $468 $119–$2,323 $164
2025 $12,139 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Argenx US, Inc. $5,424 31 payments
  2. AbbVie, Inc. $1,449 102 payments
  3. Alexion Pharmaceuticals, Inc. $1,431 53 payments
  4. UCB, Inc. $1,208 52 payments
  5. Harmony Biosciences LLC $1,030 49 payments
  6. Biogen, Inc. $994 31 payments
  7. Jazz Pharmaceuticals Inc. $969 50 payments
  8. Teva Pharmaceuticals USA, Inc. $792 45 payments
  9. Novartis Pharmaceuticals Corporation $785 61 payments
  10. ACADIA Pharmaceuticals Inc $750 35 payments
  11. Other $10,757 562 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,186 1,055 payments
  2. Consulting Fee $3,800 3 payments
  3. Travel and Lodging $1,167 7 payments
  4. Education $437 6 payments
Products named General payments · program years 2019–2025
  1. VYVGART Hytrulo $5,140 25 payments
  2. ULTOMIRIS $1,381 51 payments
  3. UBRELVY $1,075 72 payments
  4. QULIPTA $975 76 payments
  5. XYWAV $833 38 payments
  6. TYSABRI $780 24 payments
  7. NUPLAZID $692 32 payments
  8. Briviact $686 23 payments
  9. INGREZZA $662 45 payments
  10. Austedo XR $652 39 payments
  11. Other $12,325 686 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

2,768

Median for Neurology: 833

Drug cost

$619,819

Median for Neurology: $202,670

Branded share of claims

24%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex (4 Pack) Interferon Beta-1a Brand 13 $124,659
Zeposia Ozanimod Hydrochloride Brand 15 $122,895
Plegridy Pen Peginterferon Beta-1a Brand 12 $100,224
Trokendi Xr Topiramate Brand 37 $54,651
Aimovig Autoinjector Erenumab-Aooe Brand 36 $29,418
Nurtec Odt Rimegepant Sulfate Brand 16 $25,164
Ubrelvy Ubrogepant Brand 20 $23,620
Rexulti Brexpiprazole Brand 14 $19,978
Fycompa Perampanel Brand 13 $16,222
Trileptal Oxcarbazepine Brand 12 $13,025

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$421,069

Of which drugs: $374,408

Medicare patients

270

Average age 72

Services billed

26,260

138 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 58%
Depression 37%
Diabetes 29%
Chronic kidney disease 29%
Ischemic heart disease 28%
COPD 19%
Alzheimer's or dementia 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 61 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
$464 — —
Briviact
$383 — —
WAKIX
$355 — —
Austedo XR
$355 — —
XYWAV
$320 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 61 with Patron

Records

1,071 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record